E-Therapeutics plc Announces Resignation of Sean Nicolson as Executive Director & Company Secretary, Effective February 28, 2017

e-therapeutics plc is a United Kingdom-based company engaged in integrating computational power and biological data to discover life-transforming RNA interference (RNAi) medicines. The Company's technology uses computation to capture and model human biology, identify targets, and develop RNAi medicines against those targets that can be progressed to the clinic. Its HepNet platform enables the generation and analysis of biological network models, providing a mechanistic approach to drug discovery. Its RNAi platform, GalOmic, enables targeted delivery to hepatocytes in the liver and the specific silencing of disease-associated genes, identified by HepNet. The Company is progressing a pipeline of RNAi candidates across a variety of therapeutic areas with high unmet need, including preclinical programs in cardiometabolic and metabolic diseases, hemophilia, and other undisclosed indications. Its pipeline includes ETX-312, ETX-407, ETX-148, ETX-291 and others.